(Q34992719)

5 August 2017

title

High-density lipoproteins and coronary artery disease: a single-center cohort study (English)

1 reference

5 August 2017

main subject

coronary artery disease

1 reference

5

Harry Suryapranata

1 reference

5 August 2017

Alon Schaffer

1

1 reference

5 August 2017

Monica Verdoia

2

1 reference

5 August 2017

Lucia Barbieri

3

1 reference

5 August 2017

Toni Mustahsani Aprami

4

1 reference

5 August 2017

Paolo Marino

6

1 reference

5 August 2017

Giuseppe De Luca

7

1 reference

5 August 2017

Novara Atherosclerosis Study Group (NAS)

8

1 reference

5 August 2017

publication date

18 September 2013

1 reference

5 August 2017

1 reference

5 August 2017

volume

65

1 reference

5 August 2017

issue

8

1 reference

5 August 2017

page(s)

696-702

1 reference

Coronary artery disease in the developing world

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

The forgotten majority: unfinished business in cardiovascular risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

High-density lipoprotein metabolism: potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Reverse cholesterol transport: high-density lipoprotein's magnificent mile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Mean platelet volume and the extent of coronary artery disease: results from a large prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

The role of lipids and lipoproteins in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

HDL particle size: a marker of the gender difference in the metabolic risk profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

High-density lipoprotein: antioxidant and anti-inflammatory properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Low high-density lipoprotein cholesterol: current status and future strategies for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment dura

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Safety of anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713502253

21 January 2018

Identifiers

DOI

10.1177/0003319713502253

1 reference

5 August 2017

1 reference